China Human Papilloma Virus/HPV Test and Pap Smear/Test Market (2025-2030)
The China Human Papilloma Virus/HPV Test and Pap Smear/Test Market was valued at $108.7 Million in 2025 and projected to reach to $242.2 Million by 2030, representing a compound annual growth rate of CAGR 17.4%. China's HPV test and Pap smear market is positioned for exceptional growth through 2030, driven by government healthcare initiatives, rising cervical cancer awareness, and expanding healthcare infrastructure.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China Human Papilloma Virus/HPV Test and Pap Smear/Test Market Trends and Insights
- This represents a compound annual growth rate of 17.4%, significantly outpacing global market growth.
- China's rapid market acceleration is driven by increasing cervical cancer awareness, government screening initiatives, and rising healthcare expenditure across urban and rural regions. The market in China is benefiting from improved access to diagnostic infrastructure and growing adoption of HPV testing as a primary screening method over traditional Pap smears.
- China's expanding middle class and enhanced reimbursement policies are fueling demand for preventive healthcare services.
- Between 2025 and 2030, China is expected to solidify its position as a key growth engine within the Asia Pacific region, with technological advancements and public health campaigns further accelerating market penetration. China's cervical cancer screening programs, supported by both public and private healthcare providers, are creating substantial opportunities for market participants.
- The shift toward HPV-based testing in China reflects global best practices and regulatory support, positioning the country as a critical market for diagnostic manufacturers and healthcare providers..
Key Market Statistics
- CAGR (2025-2030) CAGR 17.4%
- Market Size, 2025 ~USD 108.7 Million
- Forecast, 2030 ~USD 242.2 Million
- Country China
China Human Papilloma Virus/HPV Test and Pap Smear/Test Market Overview
Exceptional Growth Trajectory :
China's HPV test and Pap smear market is expanding at 17.4% CAGR, nearly double the global rate of 10%, reflecting accelerating adoption and market maturation in the world's most populous nation.
Government-Backed Screening Initiatives :
National cervical cancer prevention programs and government-funded screening campaigns are driving widespread testing adoption across urban and rural regions, significantly expanding market accessibility.
Rising Cervical Cancer Awareness :
Increased public health education and media campaigns have elevated awareness of HPV-related risks among Chinese women, translating into higher screening participation rates and market demand.
Market Valuation Surge :
The market is projected to more than double from USD 108.7 million in 2025 to USD 242.2 million by 2030, representing substantial investment opportunities and revenue growth potential.
China Human Papilloma Virus/HPV Test and Pap Smear/Test Market Dynamics
- The 17.4% CAGR significantly outpaces global benchmarks, reflecting China's commitment to preventive healthcare and women's health screening programs.
- Increasing urbanization, improved access to diagnostic facilities, and growing disposable incomes are enabling broader population screening coverage.
- Additionally, technological advancements in testing methodologies and integration with digital health platforms are enhancing market penetration.
- The market's trajectory suggests sustained expansion as China continues prioritizing cervical cancer prevention as a public health priority..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- China's HPV test and Pap smear market is projected to more than double from USD 108.7 million (2025) to USD 242.2 million (2030), driven by a 17.4% CAGR.
- China's market growth significantly exceeds the global average, reflecting strong government support for cervical cancer screening and preventive healthcare initiatives.
- HPV testing adoption in China is accelerating as the preferred screening method, replacing traditional Pap smears in many healthcare settings.
- Rising healthcare expenditure, improved diagnostic infrastructure, and expanding insurance coverage in China are key catalysts for sustained market expansion through 2030.
Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | VAGINAL CANCER SCREENING (Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 10% from 2025 to 2030 |
| Largest Segment | CERVICAL CANCER SCREENING (Application) |
| Market Size Base Year (Billions) | ~USD 2.45 (2025) |
| Revenue Forecast (Billions) | ~USD 3.94 (2030) |
| Segments Covered | Product & Service, Test Type, Type, Technology, Application, Care Setting |
China Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product & Service
- Consumables
- Instruments
- Services
By Test Type
- Hpv Testing
- Pap Tests
By Type
- Co-Testing
- Follow-Up Hpv Testing
- Primary Hpv Testing
By Technology
- Cytology
- Immunodiagnostics
- Molecular Diagnostics
By Application
- Cervical Cancer Screening
- Vaginal Cancer Screening
By Care Setting
- Diagnostic Laboratories
- Hospitals
- Physicians’ Offices & Clinics
CHINA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CERVICAL CANCER SCREENING | 144.7 | 157.3 | 174 | 194.4 | 219.4 | 250.6 | 288.3 | 335.5 | 14 |
| VAGINAL CANCER SCREENING | 11.2 | 12.4 | 13.9 | 15.7 | 18 | 20.9 | 24.3 | 28.7 | 15.6 |
| TOTAL | 155.9 | 169.7 | 187.9 | 210.1 | 237.5 | 271.5 | 312.6 | 364.3 | 14.2 |
Target Audience
- Medical Device Manufacturers : Need China market data to develop localized HPV testing solutions, understand regulatory requirements, and identify distribution partnerships in this rapidly expanding diagnostic market.
- Healthcare Investors & PE Firms : Require detailed market sizing and growth forecasts for China to evaluate investment opportunities in diagnostic companies, screening platforms, and healthcare infrastructure providers.
- Pharmaceutical & Diagnostics Companies : Need competitive intelligence and market dynamics specific to China to inform product development, pricing strategies, and market entry timelines for HPV-related solutions.
- Government & Public Health Agencies : Require market analysis to support cervical cancer prevention policy development, resource allocation for screening programs, and evaluation of public health initiative effectiveness.
- Healthcare Consultants & Analysts : Need comprehensive China market data to advise clients on market opportunities, competitive positioning, and strategic recommendations within the HPV testing and cervical cancer screening sector.
Key Companies in the China Human Papilloma Virus/HPV Test and Pap Smear/Test Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOMERIEUX S.A. | France | Public Company | Microbiology & AST (VITEK 2, VITEK MS, VITEK REVEAL, API, ETEST, CHROMID, culture media),Molecular & Syndromic (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, BIOMERIEUX EPISEQ CS),Immunoassay & Sepsis (VIDAS, Hybiome CLIA), |
| INTERTEK GROUP PLC | United Kingdom | Public Company | Consumer Products,Corporate Assurance,Health and Safety, |
| QUIDEL CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care, |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, localization, software),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa, CoolSeal), |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and molecular diagnostics assays,PCR and digital PCR solutions, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and single-use solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables), |
| ABBOTT | United States | Public Company | Medical Devices,Diagnostic Products,Nutritional Products, |
| SEEGENE INC. | South Korea | Public Company | Respiratory infectious disease panels,Sexually transmitted infection and HPV assays,Gastrointestinal and meningitis syndromic panels, |
| SD BIOSENSOR, INC. | South Korea | Public Company | STANDARD Q rapid diagnostics,STANDARD F fluorescence immunodiagnostics,STANDARD E enzyme immunoassay, |
| SANSURE BIOTECH INC. | China | Public Company | Nucleic acid diagnostic reagents (respiratory, HPV, reproductive, blood-borne, GI, others),Rapid antigen tests,Nucleic acid extraction and purification kits, sample reagents, |
| MOLBIO DIAGNOSTICS LIMITED | India | Private Company | Truenat PCR platforms (instruments),Truenat assays and reagents,Disposable POCT devices (dengue, malaria, COVID-19, others), |
BIOMERIEUX S.A.
bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company specializes in in vitro diagnostics and microbiology testing solutions.
INTERTEK GROUP PLC
Intertek Group PLC is a British public company established in 1885 with 45,425 employees. The company offers testing, inspection, and certification services across multiple industries.
QUIDEL CORPORATION
Quidel Corporation is a United States public company founded in 1979 with 6,500 employees. The company manufactures rapid diagnostic testing products and molecular assays.
HOLOGIC, INC.
Hologic, Inc. is a private United States company founded in 1985 with 7,070 employees. The company develops and manufactures diagnostic and medical imaging products.
QIAGEN
QIAGEN is a Dutch public company founded in 1984 with 5,500 employees. The company provides molecular diagnostics, sample preparation, and life sciences research tools.
DANAHER CORPORATION
Danaher Corporation is a United States public company founded in 1969 with 59,000 employees. The company operates across diagnostics, life sciences, and environmental solutions.
ABBOTT
Abbott is a United States public company founded in 1888 with 115,000 employees. The company is a diversified healthcare company providing diagnostics, medical devices, and pharmaceuticals.
SEEGENE INC.
Seegene Inc. is a South Korean public company founded in 2000 with 216 employees. The company specializes in molecular diagnostic testing and multiplex PCR technology.
SD BIOSENSOR, INC.
SD Biosensor, Inc. is a South Korean public company founded in 1999 with 576 employees. The company develops and manufactures rapid diagnostic test kits and point-of-care devices.
SANSURE BIOTECH INC.
Sansure Biotech Inc. is a Chinese public company founded in 2008 with 2,128 employees. The company develops molecular diagnostic reagents and testing solutions.
MOLBIO DIAGNOSTICS LIMITED
Molbio Diagnostics Limited is a private Indian company founded in 2000. The company develops and manufactures molecular diagnostic devices and testing solutions.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation data for China (USD 108.7M in 2025) with verified 17.4% CAGR projections through 2030, enabling accurate business planning and investment decisions.
- Competitive Landscape Intelligence : Understand China-specific market dynamics, key players, and competitive positioning to identify market entry opportunities and strategic partnerships in this high-growth segment.
- Government Policy & Regulatory Insights : Access detailed analysis of China's national screening initiatives, healthcare policies, and regulatory frameworks driving market expansion and shaping future opportunities.
- Regional Expansion Strategy : Leverage China-focused market segmentation data to develop targeted expansion strategies across urban centers and emerging markets, maximizing market penetration and revenue potential.
- Investment & Forecasting Accuracy : Make informed investment decisions with China-specific forecasts through 2030, including market drivers, barriers, and growth catalysts essential for financial planning and ROI projections.
Frequently asked questions
What is the current market size of HPV testing and Pap smears in China?
China's HPV test and Pap smear market was valued at USD 108.7 million in 2025 and is expected to grow to USD 242.2 million by 2030.
What is the projected growth rate for China's HPV testing market?
China's market is projected to grow at a compound annual growth rate (CAGR) of 17.4% from 2025 to 2030, significantly outpacing global growth.
Why is China's HPV testing market growing faster than the global average?
China's accelerated growth is driven by government cervical cancer screening programs, rising healthcare awareness, improved diagnostic infrastructure, and expanding insurance coverage.
Is HPV testing replacing Pap smears in China?
Yes, China is experiencing a gradual shift toward HPV-based testing as the primary screening method, though Pap smears remain in use alongside HPV tests in many facilities.
What factors are supporting market expansion in China through 2030?
Key drivers include increased cervical cancer awareness, government health initiatives, rising disposable incomes, improved healthcare access in rural areas, and technological advancements in diagnostic testing.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global HPV testing and Pap test market.
Exhaustive secondary research was done to collect information on the HPV testing and Pap test market. The next step was to validate these findings, assumptions, and sizes with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the HPV testing and Pap test market.
Four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the HPV testing and Pap test market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:
- The key players in the industry have been identified through extensive secondary research.
- The revenues generated by leading players operating in the HPV testing and Pap test market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size included the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Human Papillomavirus (HPV) testing identifies the presence of high-risk HPV strains that can lead to cervical cancer and related abnormalities. It is increasingly adopted as a primary screening approach, either independently or alongside Pap testing (co-testing), to assess the risk of cervical disease.
The Papanicolaou (Pap) test is a cytological screening procedure used to detect precancerous and cancerous cells in the cervix, which connects the uterus and vagina. While primarily applied in cervical cancer screening, Pap tests can also detect abnormal or malignant cells in the vaginal canal in some cases.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global HPV testing and Pap test market by product & service, test type, technology, application, care setting, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall HPV testing and Pap test market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the HPV testing and Pap test market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region
Get the Full Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report
Full forecast, segment splits, and company analysis for all Human Papilloma Virus/HPV Test and Pap Smear/Test Market.
- US Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Canada Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Germany Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- UK Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- France Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Italy Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Spain Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Japan Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- India Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Brazil Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Mexico Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Saudi Arabia Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- UAE Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Asia Pacific Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Latam Human Papilloma Virus/HPV Test and Pap Smear/Test Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
